Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 9/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.34 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | MERTK | Q12866 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 4/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | PRKCA | P17252 | 2/20 | 0.32 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8964990 | 0.82 | PRKCQ (0.66) | PRKCQPRKCAPRKCD | |
| SCHEMBL8970017 | 0.74 | PRKCQ (0.55) | PRKCQPRKCAPRKCD | |
| SCHEMBL8965423 | 0.72 | PRKCQ (0.66) | PRKCQPIM1PIM2PRKCAPRKCD | |
| SCHEMBL9011911 | 0.69 | PRKCQ (0.46) | PRKCQPIM1PIM2PRKCAPRKCD | |
| SCHEMBL9013152 | 0.69 | PRKCQ (0.68) | PRKCQPIM1PIM2PRKCAPRKCD | |
| SCHEMBL8970227 | 0.68 | PRKCQ (0.53) | PRKCQPRKCAPRKCD | |
| SCHEMBL9008887 | 0.68 | PRKCQ (0.71) | PRKCQPRKCAPRKCD | |
| SCHEMBL13857209 | 0.67 | PRKCQ (0.74) | PRKCQPRKCAPRKCD | |
| SCHEMBL8965676 | 0.67 | PRKCQ (0.74) | PRKCQPRKCAPRKCD | |
| SCHEMBL8965901 | 0.67 | PRKCQ (0.61) | PRKCQPARP1PRKCAPRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221334-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221334-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221334-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | PRKCQ 38/4885PARP1 862/4885MAPK1 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.